COVID-19 Huashi Baidu Formula Clinical Study

• Status: Not yet recruiting
• Trial end date: 2024-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Combined with the regional and population characteristics of Asia and Africa, Huashi Baidu Granule was used to intervene in mild and ordinary patients with COVID-19, evaluate its efficacy and safety, and clarify its characteristics of action.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Xiyuan Hospital of China Academy of Chinese Medical Sciences
• Collaborators: Beijing YouAn Hospital; Kamuzu University of Health Sciences; Kossamak Hospital

Criteria

Inclusion Criteria:

1. Conform to the diagnostic criteria for COVID-19 mild and common in the Diagnosis and Treatment Plan for novel coronavirus Pneumonia (Trial Version 9) ；

2. Age ≥ 18 years and ≤ 65 years;

3. The time from the first symptom (or confirmed onset) shall not exceed 5 days;

4. If the patient agrees to participate in the study, he/she will sign the informed consent form through paper signature, electronic signature of mobile software or voice authorization.

Exclusion Criteria:

1. Patients who cannot guarantee the compliance of taking medicine during the treatment period, and who are difficult to take medicine by oral or nasal feeding.

2. Patients with severe primary respiratory diseases or other pathogenic microorganism pneumonia that needs to be differentiated from COVID-19.

3. Pregnant women, with positive urine pregnancy test, or with pregnancy plan within 12 months.

4. Patients suffering from malignant tumors, mental diseases and other systematic malignant diseases that the researchers consider unsuitable for the study.

5. People who have ever been allergic to the test drug and who do not tolerate the drug.

6. Those who are participating in other clinical trials.

7. Non severe patients in the trial shall not enter the study again after changing the classification.